DME/Retina Edition: Top Headlines for Week of June 3, 2024

In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. Read the full coverage here:

VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema

Merck to acquire EyeBio

VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME

Phase 2 study of potential DME oral therapy meets primary endpoints

FDA approves aflibercept biosimilars Yesafili, Opuviz

References:

Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.

Luvisi J. Using a convolutional neural network to predict response of diabetic macular edema to intravitreal anti-vascular endothelial growth factor. Presented at: Kiawah Eye; May 30-June 1, 2024; Kiawah Island, South Carolina.

Press Release

Press Release

Press Release